Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 6/2018

01-11-2018 | Original Article

Tumor necrosis factor receptor-associated factor 6 is required to inhibit foreign body giant cell formation and activate osteoclasts under inflammatory and infectious conditions

Authors: Akihito Oya, Eri Katsuyama, Mayu Morita, Yuiko Sato, Tami Kobayashi, Kana Miyamoto, Toru Nishiwaki, Atsushi Funayama, Yoshinari Fujita, Takashi Kobayashi, Morio Matsumoto, Masaya Nakamura, Arihiko Kanaji, Takeshi Miyamoto

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2018

Login to get access

Abstract

Osteoclasts and foreign body giant cells (FBGCs) are derived from common progenitors and share properties such as multi-nucleation capacity induced by cell–cell fusion; however, mechanisms underlying lineage determination between these cells remain unclear. Here we show that, under inflammatory conditions, osteoclasts are stimulated in a manner similar to M1 macrophages, while formation of FBGCs, which exhibit M2-like phenotypes, is inhibited in a manner similar to that seen in M1/M2 macrophage polarization. FBGC/osteoclast polarization was inhibited by conditional knockout of tumor necrosis factor receptor associated factor 6 (Traf6) in adults in vivo and in vitro. Traf6-null mice were previously reported to die soon after birth, but we found that Traf6 deletion in adults did not cause lethality but rather inhibited osteoclast activation and prevented FBGC inhibition under inflammatory conditions. Accordingly, basal osteoclastogenesis was significantly inhibited by Traf6 deletion in vivo and in vitro and accompanied by increased bone mass. Lipopolysaccharide-induced osteoclast formation and osteolysis were significantly inhibited in Traf6 conditional knockout mice. Our results suggest that Traf6 plays a crucial role in regulating M1 osteoclast and M2 FBGC polarization and is a potential therapeutic target in blocking FBGC inhibition, antagonizing osteolysis in inflammatory conditions, and increasing bone mass without adverse effects in adults.
Appendix
Available only for authorised users
Literature
2.
go back to reference Tang L, Eaton JW (1995) Inflammatory responses to biomaterials (in Eng). Am J Clin Pathol 103:466–471CrossRef Tang L, Eaton JW (1995) Inflammatory responses to biomaterials (in Eng). Am J Clin Pathol 103:466–471CrossRef
3.
go back to reference Tang L, Eaton JW (1999) Natural responses to unnatural materials: a molecular mechanism for foreign body reactions (in Eng). Mol Med 5:351–358CrossRef Tang L, Eaton JW (1999) Natural responses to unnatural materials: a molecular mechanism for foreign body reactions (in Eng). Mol Med 5:351–358CrossRef
4.
go back to reference Anderson JM (1988) Inflammatory response to implants (in Eng). ASAIO Trans 34:101–107CrossRef Anderson JM (1988) Inflammatory response to implants (in Eng). ASAIO Trans 34:101–107CrossRef
6.
go back to reference Aronson M, Elberg SS (1962) Fusion of peritoneal histocytes with formation of giant cells (in Eng). Nature 193:399–400CrossRef Aronson M, Elberg SS (1962) Fusion of peritoneal histocytes with formation of giant cells (in Eng). Nature 193:399–400CrossRef
9.
go back to reference Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y (2006) v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation (in Eng). Nat Med 12:1403–1409. https://doi.org/10.1038/nm1514 CrossRefPubMed Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y (2006) v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation (in Eng). Nat Med 12:1403–1409. https://​doi.​org/​10.​1038/​nm1514 CrossRefPubMed
10.
go back to reference Saginario C, Sterling H, Beckers C, Kobayashi R, Solimena M, Ullu E, Vignery A (1998) MFR, a putative receptor mediating the fusion of macrophages (in Eng). Mol Cell Biol 18:6213–6223CrossRef Saginario C, Sterling H, Beckers C, Kobayashi R, Solimena M, Ullu E, Vignery A (1998) MFR, a putative receptor mediating the fusion of macrophages (in Eng). Mol Cell Biol 18:6213–6223CrossRef
12.
go back to reference Sterling H, Saginario C, Vignery A (1998) CD44 occupancy prevents macrophage multinucleation (in Eng). J Cell Biol 143:837–847CrossRef Sterling H, Saginario C, Vignery A (1998) CD44 occupancy prevents macrophage multinucleation (in Eng). J Cell Biol 143:837–847CrossRef
15.
go back to reference Miyamoto H, Suzuki T, Miyauchi Y, Iwasaki R, Kobayashi T et al (2012) Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell–cell fusion to form osteoclasts and foreign body giant cells (in Eng). J Bone Miner Res 27:1289–1297. https://doi.org/10.1002/jbmr.1575 CrossRefPubMed Miyamoto H, Suzuki T, Miyauchi Y, Iwasaki R, Kobayashi T et al (2012) Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell–cell fusion to form osteoclasts and foreign body giant cells (in Eng). J Bone Miner Res 27:1289–1297. https://​doi.​org/​10.​1002/​jbmr.​1575 CrossRefPubMed
18.
go back to reference Katsuyama E, Miyamoto H, Kobayashi T, Sato Y, Hao W, Kanagawa H, Fujie A, Tando T, Watanabe R, Morita M, Miyamoto K, Niki Y, Morioka H, Matsumoto M, Toyama Y, Miyamoto T (2015) Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells. J Biol Chem 290:716–726. https://doi.org/10.1074/jbc.M114.568360 CrossRefPubMed Katsuyama E, Miyamoto H, Kobayashi T, Sato Y, Hao W, Kanagawa H, Fujie A, Tando T, Watanabe R, Morita M, Miyamoto K, Niki Y, Morioka H, Matsumoto M, Toyama Y, Miyamoto T (2015) Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells. J Biol Chem 290:716–726. https://​doi.​org/​10.​1074/​jbc.​M114.​568360 CrossRefPubMed
25.
go back to reference Wajant H, Grell M, Scheurich P (1999) TNF receptor associated factors in cytokine signaling (in Eng). Cytokine Growth Factor Rev 10:15–26CrossRef Wajant H, Grell M, Scheurich P (1999) TNF receptor associated factors in cytokine signaling (in Eng). Cytokine Growth Factor Rev 10:15–26CrossRef
27.
go back to reference Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C et al (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling (in Eng). Genes Dev 13:1015–1024CrossRef Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C et al (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling (in Eng). Genes Dev 13:1015–1024CrossRef
28.
go back to reference Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice (in Eng). Genes Cells 4:353–362CrossRef Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice (in Eng). Genes Cells 4:353–362CrossRef
29.
go back to reference Gohda J, Matsumura T, Inoue J (2004) Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling (in Eng). J Immunol 173:2913–2917CrossRef Gohda J, Matsumura T, Inoue J (2004) Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling (in Eng). J Immunol 173:2913–2917CrossRef
38.
go back to reference Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T (1999) Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434–442PubMed Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T (1999) Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434–442PubMed
39.
go back to reference Lomaga MA, Henderson JT, Elia AJ, Robertson J, Noyce RS, Yeh WC, Mak TW (2000) Tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS (in Eng). J Neurosci 20:7384–7393CrossRef Lomaga MA, Henderson JT, Elia AJ, Robertson J, Noyce RS, Yeh WC, Mak TW (2000) Tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS (in Eng). J Neurosci 20:7384–7393CrossRef
Metadata
Title
Tumor necrosis factor receptor-associated factor 6 is required to inhibit foreign body giant cell formation and activate osteoclasts under inflammatory and infectious conditions
Authors
Akihito Oya
Eri Katsuyama
Mayu Morita
Yuiko Sato
Tami Kobayashi
Kana Miyamoto
Toru Nishiwaki
Atsushi Funayama
Yoshinari Fujita
Takashi Kobayashi
Morio Matsumoto
Masaya Nakamura
Arihiko Kanaji
Takeshi Miyamoto
Publication date
01-11-2018
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 6/2018
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-017-0890-z

Other articles of this Issue 6/2018

Journal of Bone and Mineral Metabolism 6/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.